<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078101</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT-Nr: 2016-002935-14</org_study_id>
    <nct_id>NCT03078101</nct_id>
  </id_info>
  <brief_title>EMPRA (EMPagliflozin and RAs in Kidney Disease)</brief_title>
  <acronym>EMPRA</acronym>
  <official_title>Effect of Empagliflozin on the Renin-angiotensin System in Patients With Chronic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Attoquant Diagnostics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a prospective, clinical pilot study in CKD patients to show whether&#xD;
      Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels compared&#xD;
      to ACEi treatment alone.&#xD;
&#xD;
      Null and alternative hypotheses:&#xD;
&#xD;
      H0: Empagliflozin in addition to ACEi treatment does not increase Ang 1-7 levels more than&#xD;
      ACEi treatment alone.&#xD;
&#xD;
      H1: Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels&#xD;
      compared to ACEi treatment alone&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Two groups of 24 chronic kidney disease (CKD) patients, respectively, with and without type 2&#xD;
      diabetes will be randomized into the study medication or placebo group. The number of&#xD;
      patients per treatment arms is n = 12. Included and consented patients will be subjected to&#xD;
      an initial 2-week run-in period for conversion of current RAS blocking medications to ACEi&#xD;
      therapy with enalapril or ramipril and respective dose titration to 10 mg enalapril 2 x daily&#xD;
      and 10 mg ramipril 1 x daily. Additional antihypertensive medication will be standardized as&#xD;
      feasible, with the primary goal of keeping blood pressure as recommended by KDIGO. Following&#xD;
      the 2-week run-in phase, all study patients will be subjected to blood collection including&#xD;
      the first RAS quantification (RAS Fingerprint) and assessment of HDL composition, as well as&#xD;
      urinary analysis and bioimpedance fluid status assessment (BCM measurement). Subsequently,&#xD;
      patients will be randomized to either receive empagliflozin (at a dose of 10 mg daily) or&#xD;
      placebo. Subsequently, biweekly study visits including electrolyte and glucose (plasma and&#xD;
      urine) monitoring as well as BCM measurement will take place. After 12 weeks of study&#xD;
      medication intake, a concluding study visit will be scheduled for final RAS quantification&#xD;
      (RAS Fingerprint) and HDL analyses as well as final blood and urinary analysis and BCM&#xD;
      measurement. Initially, blood and urine will be collected at the clinical visit as part of&#xD;
      the routine blood obtainment (no additional effort on patients). From these routine&#xD;
      measurements we will be able to extract information regarding the patient's current CKD stage&#xD;
      as well as other relevant laboratory parameters (e.g. HbA1c, UACR, etc.). Furthermore, we&#xD;
      will document the patient's current medication and significant comorbidities.&#xD;
&#xD;
      Primary analysis variable/endpoint:&#xD;
&#xD;
      The difference of Ang 1-7 increase from baseline between a 3-month treatment with&#xD;
      empagliflozin on top of ACEi treatment compared to ACEi treatment alone&#xD;
&#xD;
      Most important secondary analysis variables/endpoints:&#xD;
&#xD;
        1. Simultaneous quantitative changes of multiple RAS effector angiotensin levels determined&#xD;
           by mass-spectrometry&#xD;
&#xD;
        2. Recurrence of Ang II levels determined by mass-spectrometry&#xD;
&#xD;
        3. HDL parameters (protein composition of HDL)&#xD;
&#xD;
        4. Renal parameters (albuminuria reduction measured by urinary albumin-creatinine ratio&#xD;
           (UACR), renal function (estimated glomerular filtration rate (GFR), serum-creatinine)&#xD;
&#xD;
        5. Urinary electrolyte levels&#xD;
&#xD;
        6. Urinary glucose levels&#xD;
&#xD;
        7. Urinary RAS metabolites (angiotensinogen, ACE and ACE2 levels, ACE2 activity)&#xD;
&#xD;
        8. Blood pressure determined by ambulatory blood pressure measurements&#xD;
&#xD;
        9. Body volume determined by bioimpedance fluid status assessment (BCM measurement)&#xD;
&#xD;
       10. OCR and ECAR in PBMCs determined by Seahorse Flux Analyzer&#xD;
&#xD;
       11. Assessment of reduction of salt sensitivity by using salt sensitivity test with&#xD;
           empagliflozin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2017</start_date>
  <completion_date type="Actual">August 7, 2019</completion_date>
  <primary_completion_date type="Actual">June 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference of Ang 1-7 increase from baseline between a 3-month treatment with empagliflozin on top of ACEi treatment compared to ACEi treatment alone</measure>
    <time_frame>Visit 2 and Visit 8; 3 months</time_frame>
    <description>The difference of Ang 1-7 increase from baseline between a 3-month treatment with empagliflozin on top of ACEi treatment compared to ACEi treatment alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean quantitative changes of baseline multiple RAS effector angiotensin levels after 3 months of empagaliflozin treatment</measure>
    <time_frame>Visit 2 and Visit 8; 3 months</time_frame>
    <description>Mean quantitative changes of baseline multiple RAS effector angiotensin levels after 3 months of empagaliflozin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes of baseline Ang II levels after 3 months of empagaliflozin treatment</measure>
    <time_frame>Visit 2 and Visit 8; : 3 months</time_frame>
    <description>Mean changes of baseline Ang II levels after 3 months of empagaliflozin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes of baseline specific protein amount on HDL after 3 months of empagaliflozin treatment</measure>
    <time_frame>Visit 2 and Visit 8; 3 months</time_frame>
    <description>Mean changes of baseline specific protein amount on HDL after 3 months of empagaliflozin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes in specific renal parameters from baseline in 3 months of empagaliflozin treatment (albuminuria reduction, renal function)</measure>
    <time_frame>Visit 2 ,3,4,5,6,7,8; 3 months</time_frame>
    <description>Mean changes in specific renal parameters from baseline in 3 months of empagaliflozin treatment (albuminuria reduction, renal function)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes from baseline relevant blood parameters (HbA1c, β-hydroxybutyrat, elektrolytes, lipids, etc.) after 3 months of empagaliflozin treatment</measure>
    <time_frame>Visit 2 ,3,4,5,6,7,8; 3 months</time_frame>
    <description>Mean changes from baseline relevant blood parameters (HbA1c, β-hydroxybutyrat, elektrolytes, lipids, etc.) after 3 months of empagaliflozin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes from baseline urinary RAS metabolites (angiotensinogen, ACE and ACE2 levels, ACE2 activity) after 3 months of empagaliflozin treatment</measure>
    <time_frame>Visit 2 and Visit 8; 3 months</time_frame>
    <description>Mean changes from baseline urinary RAS metabolites (angiotensinogen, ACE and ACE2 levels, ACE2 activity) after 3 months of empagaliflozin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes in baseline blood pressure after 3 months of empagaliflozin treatment</measure>
    <time_frame>Visit 2 ,3,4,5,6,7,8; 3 months</time_frame>
    <description>Mean changes in baseline blood pressure after 3 months of empagaliflozin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes in body fluid status after 3 months of empagaliflozin treatment</measure>
    <time_frame>Visit 2 and Visit 8; 3 months</time_frame>
    <description>Mean changes in body fluid status after 3 months of empagaliflozin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes in baseline oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) in peripheral peripheral blood mononuclear cells (PBMCs) after 3 months of empagliflozin treatment</measure>
    <time_frame>Visit 2 and Visit 8; 3 months</time_frame>
    <description>Mean changes in baseline oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) in peripheral peripheral blood mononuclear cells (PBMCs) after 3 months of empagliflozin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean changes in salt sensitivity after 3 months of empagliflozin treatment</measure>
    <time_frame>Visit 2 and Visit 8; 3 months</time_frame>
    <description>Mean changes in salt sensitivity after 3 months of empagliflozin treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of symptomatic hypoglycemia and confirmed hypoglycemic events (plasma glucose level ≤70 mg/dl or an event requiring assistance)</measure>
    <time_frame>Visit 2 ,3,4,5,6,7,8; timeframe: 3 months</time_frame>
    <description>Number of symptomatic hypoglycemia and confirmed hypoglycemic events (plasma glucose level ≤70 mg/dl or an event requiring assistance)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of adverse events reflecting urinary tract infections, genital infections, volume depletion, acute renal failure, bone fractures, diabetic ketoacidosis and thromboembolic events.</measure>
    <time_frame>Visit 2 ,3,4,5,6,7,8; 3 months</time_frame>
    <description>Number of adverse events reflecting urinary tract infections, genital infections, volume depletion, acute renal failure, bone fractures, diabetic ketoacidosis and thromboembolic events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of cardiovascular events (i.e. stroke, myocardial infarction, heart failure) during the study.</measure>
    <time_frame>Visit 2 ,3,4,5,6,7,8; 3 months</time_frame>
    <description>Number of cardiovascular events (i.e. stroke, myocardial infarction, heart failure) during the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospitalizations during the study.</measure>
    <time_frame>Visit 2 ,3,4,5,6,7,8; 3 months</time_frame>
    <description>Number of hospitalizations during the study.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Chronic Kidney Disease stage3</condition>
  <condition>Chronic Kidney Disease stage4</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Diabetic CKD patients receiving Placebo Oral Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-diabetic CKD patients receiving 'Placebo Oral Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG [Jardiance]</intervention_name>
    <description>administered orally once daily</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>administered orally once daily</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        for CKD patients with type 2 diabetes&#xD;
&#xD;
          -  Estimated GFR (calculated with the MDRD-IDMS formula) between 15 and 59 ml/min (with&#xD;
             CKD stage IIIa/b to IV)&#xD;
&#xD;
          -  Albumin excretion rates of 30-300 mg/24 hours (UACR &lt;300 mg/g)&#xD;
&#xD;
          -  Fasting plasma glucose levels &gt;126 mg/dl [7mmol/L] or HbA1c levels &gt;6.5% (Definition&#xD;
             of type 2 diabetes according to the diagnostic criteria set forth by the American&#xD;
             Diabetes Association in 2009)&#xD;
&#xD;
        for CKD patients without Diabetes&#xD;
&#xD;
          -  Estimated GFR (calculated with the MDRD-IDMS formula) between 15 and 59 ml/min (with&#xD;
             CKD stage IIIa/b to IV)&#xD;
&#xD;
          -  Albumin excretion rates of 30-300 mg/24 hours (UACR &lt;300 mg/g)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        CKD patients with type 2 diabetes&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Severely impaired renal function (eGFR &lt;15ml/min)&#xD;
&#xD;
          -  Hyperkalemia above 4.5mmol/L&#xD;
&#xD;
          -  Hypotension (systolic blood pressure lower than 120 mmHg on ambulatory measurement)&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Patients planning pregnancy&#xD;
&#xD;
          -  Body mass index &lt; 18.5 kg/m2&#xD;
&#xD;
        for CKD patients without diabetes&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Diabetic kidney disease&#xD;
&#xD;
          -  Severely impaired renal function (eGFR &lt;15ml/min)&#xD;
&#xD;
          -  Hypotension (systolic blood pressure lower than 120 mmHg on ambulatory measurement)&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Patients planning pregnancy&#xD;
&#xD;
          -  Body mass index &lt; 18.5 kg/m2 -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Hecking, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Assoc. Prof. Dr. Manfred Hecking, MD PhD</investigator_full_name>
    <investigator_title>Assoc. Prof. PD. Dr.med.</investigator_title>
  </responsible_party>
  <keyword>Empagliflozin</keyword>
  <keyword>SGLT-2 Inhibiton and RAS in CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

